Observational studyPloS one2023
Study for the validation of the FeetMe® integrated sensor insole system compared to GAITRite® system to assess gait characteristics in patients with multiple sclerosis.
Observational study in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The Effects of Different Attentional Focus During Walking on Prefrontal Cortical Activation in Young Healthy Adults.The European journal of neuroscience · 2026Article
- IMU-Based Wearable Insoles in Clinical Settings: Key Parameters Differentiating Clinical and Non-Clinical Populations.Sensors (Basel, Switzerland) · 2026Article
- Sensors in Multiple Sclerosis.Current neurology and neuroscience reports · 2025Review
- A Review of Gait Analysis Using Gyroscopes and Inertial Measurement Units.Sensors (Basel, Switzerland) · 2025Review
- Comparison of feetme insoles with a motion capture system coupled to force plates for assessing gait and posture.Scientific reports · 2025Article
- Digital remote monitoring of people with multiple sclerosis.Frontiers in immunology · 2025Review
- The FeetMeSensors (Basel, Switzerland) · 2024Article
- IoT-Based Wireless System for Gait Kinetics Monitoring in Multi-Device Therapeutic Interventions.Sensors (Basel, Switzerland) · 2024Article
- Commercial symptom monitoring devices in Parkinson's disease: benefits, limitations, and trends.Frontiers in neurology · 2024Review
- Overview on wearable sensors for the management of Parkinson's disease.NPJ Parkinson's disease · 2023Review
- Test-retest reliability of the six-minute walking distance measurements using FeetMe insoles by completely unassisted healthy adults in their homes.PLOS digital health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the concordance and statistical precision in gait velocity in people with multiple sclerosis (pwMS), measured with FeetMe® (insoles with pressure and motion sensors) compared with GAITRite® (classic reference system of gait analysis) in the timed 25-Feet Walk test (T25WT).
methodsThis observational, cross-sectional, prospective, single center study was conducted between September-2018 and April-2019 in pwMS aged 18-55 years, with Expanded Disability Status Scale (EDSS) 0-6.5 and relapse free ≥30 days at baseline. Primary endpoint was gait velocity. Secondary endpoints were ambulation time, cadence, and stride length assessment, while the correlation between gait variables and the clinical parameters of MS subjects was assessed as an exploratory endpoint.
resultsA total of 207 MS subjects were enrolled, of whom, 205 were considered in primary analysis. Most subjects were women (66.8%) and had relapsing-remitting MS (RRMS) (82.9%), with overall mean (standard deviation [SD]) age of 41.5 (8.0) year and EDSS 3.1 (2.0). There was a statistically significant (p<0.0001) and strong agreement (intra-class correlation coefficient (ICC) >0.830) in gait velocity, ambulation time and cadence assessment between FeetMe® and GAITRite®.
conclusionsAgreement between devices was strong (ICC≥0.800). FeetMe® is the first validated wearable medical device that allows gait monitoring in MS subjects, being potentially able to assess disease activity, progression, and treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.